Stroke:血清三甲胺N-氧化物浓度与高血压患者的首次卒中呈正相关

2018-08-21 xing.T MedSci原创

由此可见,较高的TMAO水平与高血压患者中首次卒中的风险增加有关。该研究的结果需要进行精心设计的临床试验来进一步证实,以更好地评估较高TMAO水平对高血压患者预后的影响。

肠源性代谢物三甲胺N-氧化物(TMAO)已被证明是具有致动脉粥样硬化的特性。目前,尚不清楚TMAO是否与首次卒中的风险相关。近日,卒中领域权威杂志Stroke上发表了一篇研究文章,研究人员旨在明确无严重血管疾病的高血压患者血清TMAO水平与首发卒中之间的关系,并评估任何可能的效应调节因素。

研究人员通过嵌套式病例对照设计,使用来自CSPPT(中国卒中一级预防试验)的数据,包含了622名首次卒中患者和622名匹配对照者。该研究在2008年5月至2013年8月期间进行,其主要结局为首次卒中。

在治疗期间调整胆碱、左旋肉碱和其他重要协变量(包括基线收缩压和时间平均收缩压)后,首次卒中的风险随着TMAO水平的增加而增加([TMAO]每增加1个自然对数比值比为1.22; 95%CI为1.02-1.46)。与血清TMAO水平为最低三分位数(<1.79μmol/ L)的参与者相比,TMAO水平位于第2三分位数(≥1.79μmol/ L;比值比为1.34; 95%CI为1.00-1.81)或TMAO水平位于第3三分位数(≥3.19μmol/ L;比值比为1.43; 95%CI为1.02-2.01)参与者发现首次卒中的风险显著更高。在探索性分析中,研究人员观察到首次卒中时TMAO水平与叶酸水平(≥7.7[中位数] vs. <7.7ng/mL)存在相互作用(相互作用P=0.030)。

由此可见,较高的TMAO水平与高血压患者中首次卒中的风险增加有关。该研究的结果需要进行精心设计的临床试验来进一步证实,以更好地评估较高TMAO水平对高血压患者预后的影响。

原始出处:

Jing Nie,et al. Serum Trimethylamine N-Oxide Concentration Is Positively Associated With First Stroke in Hypertensive Patients.Stroke. 2018. https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.021997

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2019-04-10 医者仁心

    #正相关#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-22 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-22 陈吴1239

    #三甲#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 明月清辉

    谢谢分享,学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1994516, encodeId=6c23199451697, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Apr 10 12:41:00 CST 2019, time=2019-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987444, encodeId=a44f198e444f1, content=<a href='/topic/show?id=623819e143a' target=_blank style='color:#2F92EE;'>#三甲胺N-氧化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19714, encryptionId=623819e143a, topicName=三甲胺N-氧化物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Feb 02 15:41:00 CST 2019, time=2019-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448255, encodeId=9b54144825509, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544541, encodeId=c8d8154454143, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552482, encodeId=01361552482cf, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Wed Aug 22 22:41:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026133, encodeId=764b10261334e, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Tue Aug 21 10:41:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339876, encodeId=96ed3398e694, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Aug 21 09:07:40 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339868, encodeId=7190339868fc, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9572310056, createdName=12225669m29暂无昵称, createdTime=Tue Aug 21 07:59:49 CST 2018, time=2018-08-21, status=1, ipAttribution=)]
    2018-08-21 12225669m29暂无昵称

    学习

    0

相关资讯

JASN:肾病患者肠道细菌代谢产物——TMAO——可导致心脏血管疾病的发生

肾病患者由于其尿液中有害物质不能及时排除长期在体内积累可能会导致动脉粥样硬化及心脏病的发生。集锦:• 血液中TMAO的水平,肠道细菌分解某些营养素时的代谢产物,可随着肾病加重在体内逐渐积累。• 肾移植后肾功能恢复,TMAO的水平可明显降低。• 慢性肾病患者血液中TMAO的水平较高与动脉粥样硬化风险较高以及过早死亡有关。动脉粥样硬化是导致慢性肾病(CKD)患者发生心脏病最常见的因素,而心脏病是导致肾

Heart:心衰患者谨慎食用红肉!

先前有研究表明,氧化三甲胺(TMAO)会增加慢性心衰死亡风险,近期发表在Heart的研究称,高水平的TMAO会导致急性心衰更差的预后。研究人员对972名心衰住院患者检测了循环中TMAO水平,TMAO主要来源于左旋肉碱,左旋肉碱则是在肠道消化红肉时产生。在获取TMAO检测结果后的1年随访时间里,发生了72例住院期间死亡,268例任何原因导致的死亡,384例因心衰死亡和再入院。研究结果表明,研究开始时

Nat Med:胆碱类似物或是抗栓新星,通过改变肠道细菌某种功能起作用

美国克利夫兰医学中心的研究人员聚焦于其中的一种化学物质—三甲胺N-氧化物(TMAO),进行了深入研究。

SCI REP:TMAO与死亡率相关!

总之,TMAO与死亡率有关,尤其是对于 eGFR<90 ml/min/1.73m2的个体。